GlassScriptPhysician profile
Rachel Rohaidy
NPI 1730475823
$2,819.33
in general payments reported to CMS, 2019-2025
23 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.32 · 2020: $58.90 · 2021: $454 · 2022: $841 · 2023: $433 · 2024: $629 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.34 | 2021-2025 | Vraylar, Botox |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $342.86 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $216.31 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $203.08 | 2021-2024 | Rexulti |
| Almatica Pharma LLC | $200.18 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $164.67 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.96 | 2021-2024 | Trintellix |
| Corium, LLC | $120.26 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $100.07 | 2021-2024 | Rexulti |
| Indivior INC. | $87.59 | 2021-2022 | |
| Allergan, INC. | $84.18 | 2019-2020 | |
| Axsome Therapeutics, INC. | $68.19 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $65.67 | 2022 | |
| Alkermes, INC. | $53.41 | 2022-2024 | Aristada, Vivitrol, Lybalvi |
| Bausch Health US, LLC | $40.83 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $37.73 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $23.45 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $22.66 | 2024 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $22.56 | 2025 | Adzenys Xr-Odt |
| Noven Pharmaceuticals, INC. | $19.77 | 2024 | Xelstrym |
| Ibsa Pharma INC. | $18.69 | 2022 | |
| Hikma Pharmaceuticals USA | $17.04 | 2019 | |
| Grt US Holding, INC. | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Rohaidy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.